Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Danavorexton

Generic Name: Danavorexton

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₂N_₂O_₅S

CAS Number: 2114324-48-8

Unique Ingredient Identifier: 1QMD83K4YN

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery

Phase 2

Terminated

Posted: 2023/04/14

Sponsor:Takeda

ID:NCT05814016

A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea

Phase 1

Completed

Posted: 2022/01/06

Sponsor:Takeda

ID:NCT05180890

A Study of Danavorexton in Anesthetized Adults

Phase 1

Completed

Posted: 2021/08/27

Sponsor:Takeda

ID:NCT05025397

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

Phase 1

Completed

Posted: 2019/09/16

Sponsor:Millennium Pharmaceu...

ID:NCT04091438

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

Phase 1

Completed

Posted: 2019/09/16

Sponsor:Millennium Pharmaceu...

ID:NCT04091425

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Takeda's TAK-861 Shows Promising Results in Phase 2b Trial for Narcolepsy Type 1

a year ago

Takeda's investigational oral orexin receptor 2 agonist TAK-861 demonstrated statistically significant improvements across all primary and secondary endpoints in a Phase 2b trial for narcolepsy type 1.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy